ERBB2 and non-small cell lung carcinoma: For example, the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) recommend measurement of genomic alterations in seven different genes (EGFR, ALK, ERBB2 (encodes HER2 protein), BRAF, MET, ROS1 and RET) to guide twelve different matched therapies [1].